Product Information

VYVANSE 50 MG CAPSULE is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $12.3487 per EA under NDC 59417010510. Its NADAC has been published 665 times since Nov 28, 2013.

FDA first approved this application on Feb 23, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the lisdexamfetamine dimesylate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

Price Statistics

The NADAC for VYVANSE 50 MG CAPSULE has been published 665 times since Nov 28, 2013, and over the history we have for it it has risen 109.0%. The table below summarizes its recorded NADAC range and movement.

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 78% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.